Cargando…
1559. Hematopoietic Cell Transplantation with Post-transplant Cyclophosphamide: Impact of Donor Type on Pre-engraftment Blood-Stream Infections
BACKGROUND: The aim of the study was to estimate the cumulative incidence of pre-engraftment blood stream infections (PE-BSI), its predictive factors and the infection-related mortality (IRM) after hematopoietic cell transplantation (HCT) from any donor type, with post-transplant cyclophosphamide (P...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252910/ http://dx.doi.org/10.1093/ofid/ofy210.1387 |
_version_ | 1783373374086447104 |
---|---|
author | Oltolini, Chiara Greco, Raffaella Galli, Laura Lorentino, Francesca Xue, Elisabetta Stanghellini, Maria Teresa Lupo Clerici, Daniela Giglio, Fabio Peccatori, Jacopo Bernardi, Massimo Corti, Consuelo Scarpellini, Paolo Castagna, Antonella Ciceri, Fabio |
author_facet | Oltolini, Chiara Greco, Raffaella Galli, Laura Lorentino, Francesca Xue, Elisabetta Stanghellini, Maria Teresa Lupo Clerici, Daniela Giglio, Fabio Peccatori, Jacopo Bernardi, Massimo Corti, Consuelo Scarpellini, Paolo Castagna, Antonella Ciceri, Fabio |
author_sort | Oltolini, Chiara |
collection | PubMed |
description | BACKGROUND: The aim of the study was to estimate the cumulative incidence of pre-engraftment blood stream infections (PE-BSI), its predictive factors and the infection-related mortality (IRM) after hematopoietic cell transplantation (HCT) from any donor type, with post-transplant cyclophosphamide (PT-Cy). METHODS: Retrospective cohort study on 235 adults who underwent peripheral blood HCT from every donor type with PT-Cy platform, from 2013 to 2017 at San Raffaele Scientific Institute. The Poisson regression was used to estimate the crude incidence rate (IR) of PE-BSI. The Fine-Gray competing risk model was applied to estimate the cumulative incidence function (CIF) of the first PE-BSI and its predictive factors and of IRM. RESULTS: Patients’ characteristics are reported in Table 1. During 5,316 person-days of follow-up (PDFU), 77 PE-BSI episodes occurred in 72 patients: IR = 1.45 per 100-PDFU [95% confidence interval (95% CI) 1.13–1.77]. The median time to PE-BSI was 13 days (IQR: 7–17) and the estimated CIF at 28 days was 32% (95% CI: 26–39%); no differences in CIF according to donor type [30% vs. 34% vs. 32% in match-related, match-unrelated and haploidentical donor, respectively; Gray’s test: P = 0.968]. Among the 87 isolated pathogens, 60% were Gram-positive bacteria (GPB), 39% Gram-negative bacteria (GNB) and 1% nontuberculous mycobacteria. CIFs of GNB and GPB PE-BSI by type of donor are shown in Figure 1. By multivariate analysis (Table 2), after adjustment for age, sex, year of HCT, donor type and disease phase at HCT, the CIF of any PE-BSI was higher in subjects with absolute neutrophils count ≤500 for ≥7 days before HCT [adjusted hazard ratio (AHR) = 2.90] and in multi-drug resistant (MDR) GNB rectal carriers before HCT [AHR = 2.68]. These covariates were confirmed as independent factors also for GNB PE-BSI. Overall, IRM at 30 days was 5% (95% CI: 2–8%) with no differences by donor type (Gray’s test: P = 0.106). CONCLUSION: HCT with PT-Cy platform showed a 32% of cumulative incidence of PE-BSI at 28 days and donor type did not affect its occurrence, which was conversely increased by prolonged and severe neutropenia and MDR GNB rectal carriage before HCT. Haploidentical setting did not retain a higher IRM at 30 days than match-related and match-unrelated donors. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6252910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62529102018-11-28 1559. Hematopoietic Cell Transplantation with Post-transplant Cyclophosphamide: Impact of Donor Type on Pre-engraftment Blood-Stream Infections Oltolini, Chiara Greco, Raffaella Galli, Laura Lorentino, Francesca Xue, Elisabetta Stanghellini, Maria Teresa Lupo Clerici, Daniela Giglio, Fabio Peccatori, Jacopo Bernardi, Massimo Corti, Consuelo Scarpellini, Paolo Castagna, Antonella Ciceri, Fabio Open Forum Infect Dis Abstracts BACKGROUND: The aim of the study was to estimate the cumulative incidence of pre-engraftment blood stream infections (PE-BSI), its predictive factors and the infection-related mortality (IRM) after hematopoietic cell transplantation (HCT) from any donor type, with post-transplant cyclophosphamide (PT-Cy). METHODS: Retrospective cohort study on 235 adults who underwent peripheral blood HCT from every donor type with PT-Cy platform, from 2013 to 2017 at San Raffaele Scientific Institute. The Poisson regression was used to estimate the crude incidence rate (IR) of PE-BSI. The Fine-Gray competing risk model was applied to estimate the cumulative incidence function (CIF) of the first PE-BSI and its predictive factors and of IRM. RESULTS: Patients’ characteristics are reported in Table 1. During 5,316 person-days of follow-up (PDFU), 77 PE-BSI episodes occurred in 72 patients: IR = 1.45 per 100-PDFU [95% confidence interval (95% CI) 1.13–1.77]. The median time to PE-BSI was 13 days (IQR: 7–17) and the estimated CIF at 28 days was 32% (95% CI: 26–39%); no differences in CIF according to donor type [30% vs. 34% vs. 32% in match-related, match-unrelated and haploidentical donor, respectively; Gray’s test: P = 0.968]. Among the 87 isolated pathogens, 60% were Gram-positive bacteria (GPB), 39% Gram-negative bacteria (GNB) and 1% nontuberculous mycobacteria. CIFs of GNB and GPB PE-BSI by type of donor are shown in Figure 1. By multivariate analysis (Table 2), after adjustment for age, sex, year of HCT, donor type and disease phase at HCT, the CIF of any PE-BSI was higher in subjects with absolute neutrophils count ≤500 for ≥7 days before HCT [adjusted hazard ratio (AHR) = 2.90] and in multi-drug resistant (MDR) GNB rectal carriers before HCT [AHR = 2.68]. These covariates were confirmed as independent factors also for GNB PE-BSI. Overall, IRM at 30 days was 5% (95% CI: 2–8%) with no differences by donor type (Gray’s test: P = 0.106). CONCLUSION: HCT with PT-Cy platform showed a 32% of cumulative incidence of PE-BSI at 28 days and donor type did not affect its occurrence, which was conversely increased by prolonged and severe neutropenia and MDR GNB rectal carriage before HCT. Haploidentical setting did not retain a higher IRM at 30 days than match-related and match-unrelated donors. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6252910/ http://dx.doi.org/10.1093/ofid/ofy210.1387 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Oltolini, Chiara Greco, Raffaella Galli, Laura Lorentino, Francesca Xue, Elisabetta Stanghellini, Maria Teresa Lupo Clerici, Daniela Giglio, Fabio Peccatori, Jacopo Bernardi, Massimo Corti, Consuelo Scarpellini, Paolo Castagna, Antonella Ciceri, Fabio 1559. Hematopoietic Cell Transplantation with Post-transplant Cyclophosphamide: Impact of Donor Type on Pre-engraftment Blood-Stream Infections |
title | 1559. Hematopoietic Cell Transplantation with Post-transplant Cyclophosphamide: Impact of Donor Type on Pre-engraftment Blood-Stream Infections |
title_full | 1559. Hematopoietic Cell Transplantation with Post-transplant Cyclophosphamide: Impact of Donor Type on Pre-engraftment Blood-Stream Infections |
title_fullStr | 1559. Hematopoietic Cell Transplantation with Post-transplant Cyclophosphamide: Impact of Donor Type on Pre-engraftment Blood-Stream Infections |
title_full_unstemmed | 1559. Hematopoietic Cell Transplantation with Post-transplant Cyclophosphamide: Impact of Donor Type on Pre-engraftment Blood-Stream Infections |
title_short | 1559. Hematopoietic Cell Transplantation with Post-transplant Cyclophosphamide: Impact of Donor Type on Pre-engraftment Blood-Stream Infections |
title_sort | 1559. hematopoietic cell transplantation with post-transplant cyclophosphamide: impact of donor type on pre-engraftment blood-stream infections |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252910/ http://dx.doi.org/10.1093/ofid/ofy210.1387 |
work_keys_str_mv | AT oltolinichiara 1559hematopoieticcelltransplantationwithposttransplantcyclophosphamideimpactofdonortypeonpreengraftmentbloodstreaminfections AT grecoraffaella 1559hematopoieticcelltransplantationwithposttransplantcyclophosphamideimpactofdonortypeonpreengraftmentbloodstreaminfections AT gallilaura 1559hematopoieticcelltransplantationwithposttransplantcyclophosphamideimpactofdonortypeonpreengraftmentbloodstreaminfections AT lorentinofrancesca 1559hematopoieticcelltransplantationwithposttransplantcyclophosphamideimpactofdonortypeonpreengraftmentbloodstreaminfections AT xueelisabetta 1559hematopoieticcelltransplantationwithposttransplantcyclophosphamideimpactofdonortypeonpreengraftmentbloodstreaminfections AT stanghellinimariateresalupo 1559hematopoieticcelltransplantationwithposttransplantcyclophosphamideimpactofdonortypeonpreengraftmentbloodstreaminfections AT clericidaniela 1559hematopoieticcelltransplantationwithposttransplantcyclophosphamideimpactofdonortypeonpreengraftmentbloodstreaminfections AT gigliofabio 1559hematopoieticcelltransplantationwithposttransplantcyclophosphamideimpactofdonortypeonpreengraftmentbloodstreaminfections AT peccatorijacopo 1559hematopoieticcelltransplantationwithposttransplantcyclophosphamideimpactofdonortypeonpreengraftmentbloodstreaminfections AT bernardimassimo 1559hematopoieticcelltransplantationwithposttransplantcyclophosphamideimpactofdonortypeonpreengraftmentbloodstreaminfections AT corticonsuelo 1559hematopoieticcelltransplantationwithposttransplantcyclophosphamideimpactofdonortypeonpreengraftmentbloodstreaminfections AT scarpellinipaolo 1559hematopoieticcelltransplantationwithposttransplantcyclophosphamideimpactofdonortypeonpreengraftmentbloodstreaminfections AT castagnaantonella 1559hematopoieticcelltransplantationwithposttransplantcyclophosphamideimpactofdonortypeonpreengraftmentbloodstreaminfections AT cicerifabio 1559hematopoieticcelltransplantationwithposttransplantcyclophosphamideimpactofdonortypeonpreengraftmentbloodstreaminfections |